Perspective
Nature Reviews Drug Discovery 1, 153-161 (February 2002) | doi:10.1038/nrd728
Innovation: Metabonomics: a platform for studying drug toxicity and gene function
Jeremy K. Nicholson1, John Connelly1, John C. Lindon1 & Elaine Holmes1 About the authors
Abstract
The later that a molecule or molecular class is lost from the drug development pipeline, the higher the financial cost. Minimizing attrition is therefore one of the most important aims of a pharmaceutical discovery programme. Novel technologies that increase the probability of making the right choice early save resources, and promote safety, efficacy and profitability. Metabonomics is a systems approach for studying in vivo metabolic profiles, which promises to provide information on drug toxicity, disease processes and gene function at several stages in the discovery-and-development process.
Author affiliations
- Jeremy K. Nicholson, John Connelly, John C. Lindon and Elaine Holmes are at the Biological Chemistry Section, Biomedical Sciences Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, South Kensington, London SW7 2AZ, UK.
Correspondence to: Jeremy K. Nicholson1 Email: j.nicholson@ic.ac.uk
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated RESEARCH |
